<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04922567</url>
  </required_header>
  <id_info>
    <org_study_id>IR2020002513</org_study_id>
    <nct_id>NCT04922567</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma</brief_title>
  <official_title>Multi-center Randomized Study to Compare Efficacy and Safety of Lenalidomide Plus CHOP (L-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Union hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southern Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of China Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongda Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jilin Provincial Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Province Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongshan Hospital Xiamen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the efficacy and safety of lenalidomide plus CHOP (L-CHOP) versus&#xD;
      CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, multi-center, open-label study to compare efficacy and safety of L-CHOP&#xD;
      with standard CHOP regimen in patients with previously untreated PTCL. Study subjects are&#xD;
      patients with histologically proven PTCL. Patients are randomized 1:1 to receive either&#xD;
      cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week&#xD;
      cycles for 6 cycles or Lenalidomide plus CHOP (L-CHOP) administered in 3 week cycles for 6&#xD;
      cycles. In the L-CHOP arm, Lenalidomide will be administered at a dose of 25mg po on day 1-10&#xD;
      every 3 weeks. This study is divided into three phases: screening phase, treatment phase and&#xD;
      follow-up phase. Patients will receive study drug(s) for up to 6 cycles, or until&#xD;
      unacceptable toxicity will develop or progression or voluntary with drawl. Adverse event of&#xD;
      every treatment cycle will be recorded. Therapy efficacy will be evaluated after finishing 3&#xD;
      cycles and finishing 6 cycles therapy. Patients will be followed until disease progression,&#xD;
      died or 3 years from the last patient randomized.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response rate</measure>
    <time_frame>At the end of Cycle 6 (each cycle is 21 days)</time_frame>
    <description>complete response (CR) and partial response (PR) rates, using the standard response criteria( 2014 Lugano criteria)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>3 years</time_frame>
    <description>from date of inclusion to date of progression, relapse, or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
    <description>From the date of inclusion to date of death, irrespective of cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>3 years</time_frame>
    <description>Any unfavorable and unintended sign , symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">289</enrollment>
  <condition>Peripheral T-Cell Lymphoma</condition>
  <condition>Lenalidomide</condition>
  <condition>CHOP</condition>
  <arm_group>
    <arm_group_label>lenalidomide + CHOP regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CHOP regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>25mg po on day 1-10</description>
    <arm_group_label>lenalidomide + CHOP regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>750mg/m² iv on day1</description>
    <arm_group_label>CHOP regimen</arm_group_label>
    <arm_group_label>lenalidomide + CHOP regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>50mg/m² iv on day 1</description>
    <arm_group_label>CHOP regimen</arm_group_label>
    <arm_group_label>lenalidomide + CHOP regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>1.4mg/m² iv on day 1</description>
    <arm_group_label>CHOP regimen</arm_group_label>
    <arm_group_label>lenalidomide + CHOP regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>100mg po on day1-5</description>
    <arm_group_label>CHOP regimen</arm_group_label>
    <arm_group_label>lenalidomide + CHOP regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically proven untreated peripheral T-cell lymphoma (include PTCL&#xD;
             not otherwise specified, angioimmunoblastic T cell lymphoma, anaplastic large cell&#xD;
             lymphoma, enteropathy-associated T cell lymphoma, Monomorphic epitheliotropic&#xD;
             intestinal T-cell lymphoma, Nodal peripheral T-cell lymphoma with T-follicular helper&#xD;
             phenotype and Follicular T-cell lymphoma).&#xD;
&#xD;
          2. Males and females of 18 years of age to 80 years of age.&#xD;
&#xD;
          3. Patients have not received anti-tumor therapy.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.&#xD;
&#xD;
          5. Fit chemotherapy indications and basic requirements, including no obvious abnormal&#xD;
             function of heart, liver, lung and kidney: creatine ≤2.0×ULN, total bilirubin&#xD;
             ≤2.0mg/dl, transaminases≤3×ULN.&#xD;
&#xD;
          6. Normal peripheral hemogram: absolute neutrophil count(ANC)≥1.5×10^9/L,&#xD;
             hemoglobin(Hb)≥90g/L, platelet(PLT)≥100×10^12/L.&#xD;
&#xD;
          7. None of other serious disease conflict with the therapeutic regimen.&#xD;
&#xD;
          8. None of other malignant tumor.&#xD;
&#xD;
          9. Pregnancy test of women at reproductive age must be negative.&#xD;
&#xD;
         10. Estimated survival time ≥ 3 months with good compliance.&#xD;
&#xD;
         11. Voluntary participation, cooperate with the experimental observation, and sign a&#xD;
             written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with the following PTCL subtypes are excluded; extranodal natural&#xD;
             killer(NK)/T-cell lymphoma, T-prolymphocytic leukemia, T large granular lymphocytic&#xD;
             leukemia, chronic lymphoproliferative disorder of NK cells, aggressive NK-cell&#xD;
             leukemia, adult T-cell leukemia/ lymphoma, hepatosplenic T-cell lymphoma, subcutaneous&#xD;
             panniculitis-like T-cell lymphoma, cutaneous T cell lymphoma, breast&#xD;
             implant-associated anaplastic large-cell lymphoma.&#xD;
&#xD;
          2. Transformed lymphoma.&#xD;
&#xD;
          3. Patients with other malignancies in the past or now; or secondary lymphoma triggered&#xD;
             by chemotherapy or radiotherapy of other malignancies.&#xD;
&#xD;
          4. Already initiated lymphoma therapy (except for the prephase treatment specified for&#xD;
             this study).&#xD;
&#xD;
          5. Patients with primary central nervous system lymphoma or lymphoma involving central&#xD;
             nervous system.&#xD;
&#xD;
          6. Patients who have central nervous system or meninges involvements.&#xD;
&#xD;
          7. Candidate for hematopoietic stem cell transplantation.&#xD;
&#xD;
          8. Known hypersensitivity to medications to be used.&#xD;
&#xD;
          9. Hemogram abnormality: ANC&lt;1.5×10^9/L; or hemoglobin&lt;90 g/L; or PLT&lt;100×10^9/L.&#xD;
&#xD;
         10. Known hepatic and renal insufficiency (creatine&gt;2.0×ULN, total bilirubin&gt;2.0&#xD;
             mg/dl，transaminases&gt;3.0×ULN).&#xD;
&#xD;
         11. Patients with decompensated heart failure; or with dilated cardiomyopathy; or with&#xD;
             coronary heart disease of non-corresponding ST-segment in ECG diagnosis; or with&#xD;
             myocardial infarction within 6 months.&#xD;
&#xD;
         12. Patients with serious uncontrolled acute infection need to be treated with antibody&#xD;
             therapies, or antiviral therapies; or serious accompanying disorder or impaired organ&#xD;
             function.&#xD;
&#xD;
         13. Know HIV-positivity; or HbsAg positivity; or hepatitis C virus-Ab positivity.&#xD;
&#xD;
         14. Pregnancy or lactation period.&#xD;
&#xD;
         15. Patients who participated in other clinical trials within 3 months.&#xD;
&#xD;
         16. The researchers considered that patients should not be in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wenbin Qian, Prof.</last_name>
    <phone>+86-13605801032</phone>
    <email>qianwb@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xianggui Yuan, Dr.</last_name>
    <phone>+86-13989883884</phone>
    <email>yuanxg@zjue.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>2nd Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenbing Qian, M.D.,PhD.</last_name>
      <phone>+8613605801032</phone>
      <email>qianwb@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 5, 2021</study_first_submitted>
  <study_first_submitted_qc>June 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

